BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Anfangning (Garsorasib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Anfangning (Garsorasib)\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07318649-2488@assetmemo.bio
DTSTAMP:20261121T004546Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Anfangning (Garsorasib): Phase 2 readout est. (NCT07318649)
DESCRIPTION:Anfangning (Garsorasib)\, phase 2.\nStudy: Phase 2 Clinical Stu
 dy to Evaluate the Efficacy\, Safety\, Tolerability\, and Pharmacokinetics
  of GH21 Capsules Combined With D-1553 Tablets in Subjects With Locally Ad
 vanced or Metastatic Solid Tumors With the KRASG12C Mutation\nEstimated pr
 imary completion: 30 December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/garsorasib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07318649
URL:https://assetmemo.bio/drug/garsorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06435455-2488@assetmemo.bio
DTSTAMP:20261121T004546Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Anfangning (Garsorasib): Phase 1/2 readout est. (NCT06435455)
DESCRIPTION:Anfangning (Garsorasib)\, phase 1/2.\nStudy: GH21 Combined With
  D-1553 in KRAS G12C Mutant Advanced Solid Tumors\nEstimated primary compl
 etion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/garsorasib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06435455
URL:https://assetmemo.bio/drug/garsorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05379946-2488@assetmemo.bio
DTSTAMP:20261121T004546Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Anfangning (Garsorasib): Phase 1/2 readout est. (NCT05379946)
DESCRIPTION:Anfangning (Garsorasib)\, phase 1/2.\nStudy: Study to Evaluate 
 D-1553 in Combination With IN10018 in Subjects With Solid Tumors\nEstimate
 d primary completion: 31 December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/garsorasib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05379946
URL:https://assetmemo.bio/drug/garsorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06166836-2488@assetmemo.bio
DTSTAMP:20261121T004546Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Anfangning (Garsorasib): Phase 1/2 readout est. (NCT06166836)
DESCRIPTION:Anfangning (Garsorasib)\, phase 1/2.\nStudy: a Study to Evaluat
 e the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mut
 ant Solid Tumors\nEstimated primary completion: 31 December 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/garsorasib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06166836
URL:https://assetmemo.bio/drug/garsorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07472478-2488@assetmemo.bio
DTSTAMP:20261121T004546Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Anfangning (Garsorasib): Phase 2 readout est. (NCT07472478)
DESCRIPTION:Anfangning (Garsorasib)\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab 
 Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIV
 EN Study)\nEstimated primary completion: 31 December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/garsorasib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07472478
URL:https://assetmemo.bio/drug/garsorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07174908-2488@assetmemo.bio
DTSTAMP:20261121T004546Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Anfangning (Garsorasib): Phase 3 readout est. (NCT07174908)
DESCRIPTION:Anfangning (Garsorasib)\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Phase 3 Study of IN10018 in Combination With D-1553 Versus Stan
 dard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With K
 RAS G12C Mutation\nEstimated primary completion: September 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/garsorasib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07174908
URL:https://assetmemo.bio/drug/garsorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07294261-2488@assetmemo.bio
DTSTAMP:20261121T004546Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Anfangning (Garsorasib): Phase 2 readout est. (NCT07294261)
DESCRIPTION:Anfangning (Garsorasib)\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NS
 CLC\nEstimated primary completion: 30 October 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/garsorasib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07294261
URL:https://assetmemo.bio/drug/garsorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
